Flumazenil
- Generic Name
- Flumazenil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H14FN3O3
- CAS Number
- 78755-81-4
- Unique Ingredient Identifier
- 40P7XK9392
- Background
Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system.
- Indication
For the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, and where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures. Also for the management of benzodiazepine overdose as an adjunct for appropriate support...
- Associated Conditions
- Sedation caused by benzodiazepine
- Associated Therapies
- Anesthesia, Reversal, Reversal of sedation therapy
Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination
- Conditions
- Interventions
- First Posted Date
- 2018-11-16
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Prisma Health-Midlands
- Registration Number
- NCT03743805
- Locations
- 🇺🇸
PRISMA Health Midlands, Columbia, South Carolina, United States
Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 36
- Registration Number
- NCT03462641
- Locations
- 🇺🇸
University of Michigan Functional Neuroimaging, Cognitive and Mobility Laboratory, Ann Arbor, Michigan, United States
Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Exposure
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 22
- Registration Number
- NCT02899156
- Locations
- 🇺🇸
UC Davis Medical Center, Sacramento, California, United States
Electro-acupuncture and Flumazenil's Effect on Sedation
- Conditions
- Interventions
- First Posted Date
- 2016-02-24
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Dr. Yin Liu
- Target Recruit Count
- 80
- Registration Number
- NCT02690389
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane
- Conditions
- Interventions
- First Posted Date
- 2014-06-06
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 36
- Registration Number
- NCT02157428
- Locations
- 🇧🇷
Hospital Universitário USP, São Paulo, Brazil
Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Yale University
- Registration Number
- NCT02048969
- Locations
- 🇺🇸
Yale Psychological Medicine Research Center, New Haven, Connecticut, United States
Safety and Pharmacokinetic Study of Sublingual Flumazenil (CRLS035) in Healthy Adults
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Coeruleus Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT01655914
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Flumazenil for the Treatment of Primary Hypersomnia
- Conditions
- Interventions
- First Posted Date
- 2010-08-17
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Lynn Marie Trotti
- Target Recruit Count
- 10
- Registration Number
- NCT01183312
- Locations
- 🇺🇸
Emory Sleep Center, Atlanta, Georgia, United States
Safety and the Efficacy of a Sublingual Administration of Flumazenil to Reverse the Effect of Hypnotic Drugs in Healthy Adults
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Coeruleus Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT01071889
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
A Randomized, Double-Blind, Placebo-Controlled Trial of Flumazenil for the Treatment of Obsessive Compulsive Disorder
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2014-04-22
- Lead Sponsor
- Parkway Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT00997087
- Locations
- 🇺🇸
James G. Sullivan, MD, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.